Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.55 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.51 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.51 |
| ▸ | TYR | P14679 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13533671 | 0.90 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL19418953 | 0.86 | ALDH1A1 (0.65) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL14178489 | 0.83 | CA12 (0.71) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL10026231 | 0.83 | CA12 (0.71) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL10061170 | 0.83 | CA12 (0.71) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL14384088 | 0.83 | CA12 (0.71) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16193444 | 0.82 | ALDH1A1 (0.55) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL16193445 | 0.82 | ALDH1A1 (0.55) | LGALS3LGALS8LGALS4ALDH1A1SMN1; SMN2 | |
| SCHEMBL8986150 | 0.82 | POLB (0.66) | ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13210176 | 0.82 | POLB (0.66) | ALDH1A1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-05-10 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-03-20 | — | — | US | disclosed |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125796-A1 | TREATMENT OF MYCOBACTERIAL INFECTION | UGCG, SMPD1, SMPD4 | LGALS3 1250/4885LGALS8 1702/4885LGALS4 982/4885 |
| US-20140080769-A1 | SUBSTRATE REDUCTION THERAPY | GBA1, SPTLC2, NPC1L1 | LGALS3 3088/4885LGALS8 3800/4885LGALS4 2729/4885 |
| US-20100022620-A1 | EPITOPE REDUCTION THERAPY | UGCG, GBA1, ENGASE | LGALS3 304/4885LGALS8 407/4885LGALS4 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.